A. D. Beadell Investment Counsel Inc. Boosts Holdings in Novo Nordisk A/S $NVO

Key Points

• A. D. Beadell Investment Counsel Inc. increased its holdings in Novo Nordisk A/S by 40.9% during the 2nd quarter, now owning a total of 24,778 shares valued at approximately $1.71 million.
• Several institutional investors showed significant interest in Novo Nordisk, with Copeland Capital Management LLC increasing its stake by 184.8% in the 1st quarter.
• Analysts have given mixed ratings on Novo Nordisk A/S, with recent downgrades from UBS Group and Wall Street Zen, while some firms upgraded the stock, leading to an average rating of "Hold" and a target price of $81.00.

A. D. Beadell Investment Counsel Inc. boosted its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 40.9% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,778 shares of the company's stock after purchasing an additional 7,193 shares during the quarter. Novo Nordisk A/S comprises 1.3% of A. D. Beadell Investment Counsel Inc.'s investment portfolio, making the stock its 29th biggest position. A. D. Beadell Investment Counsel Inc.'s holdings in Novo Nordisk A/S were worth $1,710,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of NVO. Copeland Capital Management LLC lifted its stake in Novo Nordisk A/S by 184.8% in the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock worth $27,000 after purchasing an additional 255 shares in the last quarter. North Capital Inc. purchased a new stake in shares of Novo Nordisk A/S during the 1st quarter valued at $27,000. Park Square Financial Group LLC purchased a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at $29,000. Stone House Investment Management LLC purchased a new stake in shares of Novo Nordisk A/S during the 1st quarter valued at $30,000. Finally, Disciplina Capital Management LLC raised its position in shares of Novo Nordisk A/S by 162.3% during the 1st quarter. Disciplina Capital Management LLC now owns 480 shares of the company's stock valued at $33,000 after buying an additional 297 shares in the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have recently weighed in on NVO. UBS Group cut shares of Novo Nordisk A/S from a "buy" rating to a "neutral" rating in a research report on Tuesday, August 5th. Wall Street Zen cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Saturday, August 2nd. BNP Paribas Exane upgraded shares of Novo Nordisk A/S from an "underperform" rating to a "neutral" rating and set a $54.00 price objective on the stock in a research report on Wednesday, August 13th. Berenberg Bank upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Wednesday, September 17th. Finally, Rothschild Redb upgraded shares of Novo Nordisk A/S from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, September 16th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $81.00.

Novo Nordisk A/S Price Performance

NVO stock opened at $56.07 on Friday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78. Novo Nordisk A/S has a 52 week low of $45.05 and a 52 week high of $125.62. The firm's fifty day moving average is $56.20 and its 200 day moving average is $64.68. The firm has a market cap of $250.35 billion, a P/E ratio of 15.40, a P/E/G ratio of 2.22 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.93 by $0.04. The company had revenue of $11.69 billion for the quarter, compared to analyst estimates of $77.51 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. Research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently declared a semi-annual dividend, which was paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th were issued a $0.4119 dividend. This represents a yield of 240.0%. The ex-dividend date of this dividend was Monday, August 18th. Novo Nordisk A/S's dividend payout ratio (DPR) is 22.53%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.